The ongoing generic erosion in Onfi and Sabril was partly offset by a robust performance in the core portfolio across regions, resulting in a FY19 guidance upgrade. While we believe that Lundbeck’s top-line growth could turn into the black in FY20, the margin is likely to stay under pressure due to R&D investments and the commercialisation of the recently-acquired drug, Eptinezuma.
11 Nov 2019
In line Q3; guidance upgraded for FY19
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
In line Q3; guidance upgraded for FY19
H. Lundbeck A/S Class B (LUNB:WBO) | 0 0 0.0%
- Published:
11 Nov 2019 -
Author:
Rishabh Kochar -
Pages:
3
The ongoing generic erosion in Onfi and Sabril was partly offset by a robust performance in the core portfolio across regions, resulting in a FY19 guidance upgrade. While we believe that Lundbeck’s top-line growth could turn into the black in FY20, the margin is likely to stay under pressure due to R&D investments and the commercialisation of the recently-acquired drug, Eptinezuma.